Yanan Zhu
Stock Analyst at Wells Fargo
(4.51)
# 1,029
Out of 5,116 analysts
465
Total ratings
35.8%
Success rate
12.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARCT Arcturus Therapeutics Holdings | Reiterated: Buy | $20 | $10.35 | +93.24% | 27 | Nov 6, 2026 | |
| FATE Fate Therapeutics | Rated: Hold | $2.5 → $3 | $1.84 | +63.49% | 13 | Nov 6, 2026 | |
| ONC BeOne Medicines AG | Rated: Buy | $400 → $435 | $406.96 | +6.89% | 4 | Nov 6, 2026 | |
| SRPT Sarepta Therapeutics | Reiterated: Buy | $38 | $17.82 | +113.24% | 18 | Nov 6, 2026 | |
| CYTK Cytokinetics | Reiterated: Buy | $105 | $53.69 | +95.57% | 4 | Nov 5, 2026 | |
| NAMS NewAmsterdam Pharma Company | Reiterated: Buy | $55 | $18.90 | +191.01% | 6 | Nov 5, 2026 | |
| QURE uniQure | Reiterated: Buy | $75 | $21.70 | +245.62% | 30 | Nov 5, 2026 | |
| SYRE Spyre Therapeutics | Rated: Buy | $115 | $103.86 | +10.73% | 18 | Nov 5, 2026 | |
| CRSP CRISPR Therapeutics AG | Rated: Hold | $75 → $70 | $50.07 | +39.80% | 18 | Nov 4, 2026 | |
| IOVA Iovance Biotherapeutics | Reiterated: Buy | $18 | $8.04 | +123.88% | 29 | Oct 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $87 → $110 | $93.86 | +17.20% | 2 | Oct 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $102 | $74.29 | +37.30% | 1 | Oct 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $65 | $34.39 | +89.01% | 4 | Oct 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $4 → $6 | $2.57 | +133.46% | 26 | Oct 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 | $26.41 | +165.05% | 24 | Oct 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2 | $1.75 | +14.29% | 20 | Oct 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $8.34 | +199.76% | 4 | Oct 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $49 | $9.62 | +409.36% | 1 | Sep 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 | $1.72 | +190.70% | 1 | Sep 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $15.70 | +282.17% | 2 | Aug 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $95 | $39.42 | +140.99% | 46 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $9 → $7 | $0.7094 | +886.75% | 15 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.114 | - | 22 | Jun 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $15 | $11.35 | +32.16% | 26 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $4.33 | +154.04% | 28 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.28 | +290.63% | 19 | Jan 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $4 | $1.07 | +273.83% | 9 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1.5 → $1 | $0.0199 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $11 → $0.1 | $0.0001 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $1.87 | n/a | 13 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $20.64 | n/a | 7 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $45 → $30 | $1.74 | n/a | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $272 → $326 | $927.21 | n/a | 4 | Feb 2, 2021 |
Arcturus Therapeutics Holdings
Nov 6, 2026
Reiterated: Buy
Price Target: $20
Current: $10.35
Upside: +93.24%
Fate Therapeutics
Nov 6, 2026
Rated: Hold
Price Target: $2.5 → $3
Current: $1.84
Upside: +63.49%
BeOne Medicines AG
Nov 6, 2026
Rated: Buy
Price Target: $400 → $435
Current: $406.96
Upside: +6.89%
Sarepta Therapeutics
Nov 6, 2026
Reiterated: Buy
Price Target: $38
Current: $17.82
Upside: +113.24%
Cytokinetics
Nov 5, 2026
Reiterated: Buy
Price Target: $105
Current: $53.69
Upside: +95.57%
NewAmsterdam Pharma Company
Nov 5, 2026
Reiterated: Buy
Price Target: $55
Current: $18.90
Upside: +191.01%
uniQure
Nov 5, 2026
Reiterated: Buy
Price Target: $75
Current: $21.70
Upside: +245.62%
Spyre Therapeutics
Nov 5, 2026
Rated: Buy
Price Target: $115
Current: $103.86
Upside: +10.73%
CRISPR Therapeutics AG
Nov 4, 2026
Rated: Hold
Price Target: $75 → $70
Current: $50.07
Upside: +39.80%
Iovance Biotherapeutics
Oct 29, 2026
Reiterated: Buy
Price Target: $18
Current: $8.04
Upside: +123.88%
Oct 28, 2026
Reiterated: Buy
Price Target: $87 → $110
Current: $93.86
Upside: +17.20%
Oct 15, 2026
Reiterated: Buy
Price Target: $102
Current: $74.29
Upside: +37.30%
Oct 15, 2026
Reiterated: Buy
Price Target: $65
Current: $34.39
Upside: +89.01%
Oct 8, 2026
Upgraded: Buy
Price Target: $4 → $6
Current: $2.57
Upside: +133.46%
Oct 2, 2026
Reiterated: Buy
Price Target: $70
Current: $26.41
Upside: +165.05%
Oct 2, 2026
Reiterated: Hold
Price Target: $2
Current: $1.75
Upside: +14.29%
Oct 2, 2026
Reiterated: Buy
Price Target: $25
Current: $8.34
Upside: +199.76%
Sep 29, 2026
Reiterated: Buy
Price Target: $49
Current: $9.62
Upside: +409.36%
Sep 29, 2026
Reiterated: Hold
Price Target: $5
Current: $1.72
Upside: +190.70%
Aug 31, 2026
Reiterated: Buy
Price Target: $60
Current: $15.70
Upside: +282.17%
Aug 14, 2026
Reiterated: Buy
Price Target: $95
Current: $39.42
Upside: +140.99%
Aug 11, 2026
Rated: Buy
Price Target: $9 → $7
Current: $0.7094
Upside: +886.75%
Jun 25, 2026
Rated: Hold
Price Target: n/a
Current: $0.114
Upside: -
May 12, 2026
Reiterated: Hold
Price Target: $15
Current: $11.35
Upside: +32.16%
May 7, 2026
Reiterated: Buy
Price Target: $11
Current: $4.33
Upside: +154.04%
Jan 14, 2026
Reiterated: Buy
Price Target: $5
Current: $1.28
Upside: +290.63%
Jan 13, 2026
Reiterated: Hold
Price Target: $4
Current: $1.07
Upside: +273.83%
May 14, 2025
Reiterated: Hold
Price Target: $1.5 → $1
Current: $0.0199
Upside: n/a
May 14, 2025
Downgraded: Hold
Price Target: $11 → $0.1
Current: $0.0001
Upside: n/a
May 6, 2025
Reiterated: Buy
Price Target: $10
Current: $1.87
Upside: n/a
May 16, 2024
Rated: Hold
Price Target: n/a
Current: $20.64
Upside: n/a
Aug 16, 2023
Reiterated: Hold
Price Target: $45 → $30
Current: $1.74
Upside: n/a
Feb 2, 2021
Reiterated: Hold
Price Target: $272 → $326
Current: $927.21
Upside: n/a